


Carl Zeiss Meditec AG



CARL ZEISS MEDITEC

Annual General Meeting

Weimar, 19 May 2009





1 Carl Zeiss Meditec at a glance

2 Financial year 2007/2008


3 Looking to the future

Did you know that ...

... **every second**, someone goes blind due to AMD or glaucoma?

We provide ophthalmic systems which doctors can use to diagnose these diseases at an early stage – helping them to prevent blindness.

An eye scan is carried out with these systems every second.



Did you know that ...

... in the USA alone

13,000 people die from
brain tumours each year?

Our OPMI® Pentero® microscope has
already been used in more than a million
neurosurgical interventions –
helping to provide the best possible treatment.




Did you know that ...



CARL ZEISS MEDITEC

... cataract surgery, in which the natural lens is replaced, is, with **15 million** cases each year, the most common eye surgery performed in the world?

Over 90% of cataract patients who have had our intraocular *AT-LISA lens implanted no longer need glasses.



We offer our customers a comprehensive portfolio

Hospitals, clinics,
ambulatory surgery centers

Private practitioners

Microsurgery



Surgical microscope
OPMI®Pentero®



Surgical microscope
OPMI®Sensera®



IORT:
INTRABEAM®


Ophthalmosurgery



Femtosecond laser
system: VisuMax®



Surgical microscope
OPMI Lumera®



Intraocular lens
*AT.LISA


Ophthalmology



Optical biometry:
IOLMaster®



VISULAS
Trion



OCT:
Cirrus™ HD-OCT

Innovation is the basis for our actions



CARL ZEISS MEDITEC

We at Carl Zeiss Meditec aim
to make **life more worth living for as many people as possible.**
That is the purpose behind our innovation.


In the last 160 years

we have set **a large number of milestones in ophthalmology
and microsurgery.**

We're convinced:

All human beings have the right to
sight, mobility and an active life -
for life.

Our innovations benefit doctors and patients



precision

We develop products, which, as gold standards in medicine, increase precision in diagnostics and treatment.



simplicity

Our products are designed with the medical workflow in mind. This allows the doctor to devote his full attention to his work and his patients.



outcomes

Our solutions allow our customers to achieve the best possible clinical results and obtain high levels of patient satisfaction.

Our solutions optimize the treatment of cataracts




CARL ZEISS MEDITEC





Roughly 1,300 of our 2100+ employees work outside Germany





1 Carl Zeiss Meditec at a glance

2 Financial year 2007/2008

3 Looking to the future

Financial year 2007/2008: solid performance in a challenging environment



CARL ZEISS MEDITEC

600.2

Revenue in €
million

54.0

Consolidated net income
after minorities in €
million

0.66+0.18

Earnings + dividend
per share in €

70.0

Equity ratio
in %

54.9

Operative cash flow
in € million

62.0




Investment in research
and development in €
million

New pillar Surgical Ophthalmology developing well






CARL ZEISS MEDITEC


FY 2007/2008

	Ophthalmic Systems	Surgical Ophthalmology	Microsurgery
			
Revenue by business unit	€285.0 million	€74.0 million	€241.2 million
Share in consolidated revenue	47.5 %	12.3 %	40.2 %
Growth	-2.3 %	+48.0 %	+5.8 %

Global presence largely compensated for weakness in Americas region

	Americas	EMEA	Asia/Pacific
FY 2007/2008			
Revenue by region	€ 212.8 million	€ 248.9 million	€ 138.5 million
Share in consolidated revenue	35.4 %	41.5 %	23.1 %
Growth	-12.7 %	+20.1 %	+16.6 %

Carl Zeiss Meditec share performs better than DAX and TecDAX.



Vision 2020: "The Right to Sight"



CARL ZEISS MEDITEC



AGM Agenda*



CARL ZEISS MEDITEC

- 1 Presentation of adopted annual financial statements and approved consolidated financial statements as of 30 September 2008, management report for Carl Zeiss Meditec AG and the Group for FY from 1 October 2007 to 30 September 2008 together with explanatory report of the Management Board in accordance with Art. 289 (4), 315 (4) HGB as well as Supervisory Board report.
- 2 Resolution on the distribution of retained earnings for FY 2007/2008
- 3 Resolution on the discharge of the Management Board members for FY 2007/2008
- 4 Resolution on the discharge of the Supervisory Board members for FY 2007/2008
- 5 Appointment of auditor for FY 2008/2009
- 6 Appointment of group auditor for FY 2008/2009
- 7 Resolution on authorisation to purchase treasury shares

*The following list is an overview. For precise details on the individual agenda items please see the AGM agenda.

Carl Zeiss Meditec successfully counters crisis in first six months of 2008/2009



CARL ZEISS MEDITEC

336.7

Revenue in
€ million

69.8

Equity ratio
in %

27.7

Operative cash flow
in € million



1 Carl Zeiss Meditec at a glance

2 Facts and figures


3 **Looking to the future**

Demographic trend shows growing and aging population



CARL ZEISS MEDITEC

2050: more people aged over 60 than under 14
China 2050: 7.5% of population over 80 (currently: 0.9%)



Growing demand for health services

Source: United Nations, World Population Prospects 2008

Carl Zeiss Meditec – a reliable partner



CARL ZEISS MEDITEC





RACE 2010 – Outline of our action plan



Rapid Achievement of Company Excellence 2010

Acceleration of innovation	Stronger customer focus	Focused entry into new markets
<ul style="list-style-type: none">▪ Trend and market-oriented roadmaps for innovation▪ Objective: to create new gold standards	<ul style="list-style-type: none">▪ To become a reliable partner for solutions▪ Service as unique selling point	<ul style="list-style-type: none">▪ Targeting and tapping into emerging countries▪ Exploiting external growth opportunities
Supporting and training staff		
Achieving global process excellence		

Carl Zeiss Meditec AG



CARL ZEISS MEDITEC

Annual General Meeting

Weimar, 19 May 2009

